BeyondSpring
Update in progressBYSI (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
BeyondSpring is a clinical-stage biopharmaceutical company focused on oncology and immunology. It operates two segments: the Plinabulin pipeline and the TPD platform. Lead asset Plinabulin is a selective immunomodulating microtubule-binding agent with Phase III data in NSCLC and chemotherapy-induced neutropenia. It is studied alone and in combinations with docetaxel, nivolumab, ipilimumab, pembrolizumab, and other therapies. Founded 2010, Florham Park, NJ.
Company score
- Sentiment
- 0.13
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- 0.04
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.01
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.07
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!